305-62-4

Basic information

• Product Name: 2,4-DIAMINO-BUTYRIC ACID
• Synonyms: DL-2,4-DIAMINO-N-BUTYRIC ACID;2,4-DIAMINO-BUTYRIC ACID;RARECHEM AK ZA 0003;2,4-diamino-butanoicaci;2,4-diaminobutanoicacid;alpha,gamma-diaminobutyricacid;R,S-2,4-DIAMINOBUTYRIC ACID;α,γ-Diaminobutyric acid
• CAS NO: 305-62-4
• Molecular Formula: C₄H₁₀N₂O₂
• Molecular Weight: 118.13
• EINECS: 206-166-2
• Product Categories: pharmacetical
• Mol File: 305-62-4.mol
• Article Data: 11

Chemical Properties

• Melting Point: 144 °C
• Boiling Point: 220.67°C (rough estimate)
• Appearance: /
• Density: 1.2188 (rough estimate)
• Refractive Index: 1.4386 (estimate)
• Storage Temp.: 2-8°C
• PKA: 1.85, 8.24, 10.44(at 25℃)
• CAS DataBase Reference: 2,4-DIAMINO-BUTYRIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-DIAMINO-BUTYRIC ACID(305-62-4)
• EPA Substance Registry System: 2,4-DIAMINO-BUTYRIC ACID(305-62-4)

Safety Data

• Hazardous Substances Data: 305-62-4(Hazardous Substances Data)

Usage

Uses

2,4-Diaminobutanoic Acid is a useful starting material.

Definition

ChEBI: A diamino acid that is butyric acid in which a hydrogen at position 2 and a hydrogen at position 4 are replaced by amino groups.

InChI:InChI=1/C4H10N2O2/c5-2-1-3(6)4(7)8/h3H,1-2,5-6H2,(H,7,8)

Upstream product

• 4756-09-6 propane-1,1,3-tricarboxylic acid 
• 2483-65-0 3-amino-pyrrolidin-2-one 
• 102554-90-5 Pht-D/L-Dab(Pht)-OH 
• 13591-06-5 3-thioxo-tetrahydro-pyrrolo[1,2-c]imidazole-1,5-dione 
• 149010-54-8 2-Amino-4-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-butyric acid methyl ester 
• 81546-73-8 dicyclohexylammonium N^α-benzyloxycarbonylamino-γ-nitrobutyrate 
• 77287-34-4 formamide 
• 113719-16-7 <2,6-bis(1,1-dimethylethyl)-4-methoxyphenyl>-2,4-bis(acetamido)butanoat 
• 85701-37-7 benzoylglycyl-N^γ-(pivaloyloxy)glutamine N-methylamide 
• 91861-97-1 2-Acetylamino-4-amino-N,N-diethyl-butyramide; hydrochloride 
• 87411-95-8 C₅₄H₅₄Cl₂N₈O₁₇ 

Downstream Products

• 115511-05-2 2-Amino-4-((S)-2-{(3S,4S)-4-[(S)-2-((S)-2-tert-butoxycarbonylamino-3-phenyl-propionylamino)-3-(3H-imidazol-4-yl)-propionylamino]-3-hydroxy-6-methyl-heptanoylamino}-4-methyl-pentanoylamino)-butyric acid 
• 1518-62-3 2,4-dihydroxybutanoic acid 
• 56-40-6 glycine 
• 617-45-8 aspartic Acid 
• 107-95-9 3-amino propanoic acid 
• 2483-65-0 3-amino-pyrrolidin-2-one 
• 2130-77-0 2-Amino-4-benzyloxycarbonylamino-butyric acid 
• 87394-05-6 2,4-bis-benzoylamino-butyric acid 
• 70548-52-6 N,N'-dibenzoyl methyl ester 

Relevant articles and documents

Immunomodulatory peptides

The invention relates to peptides derivatized with a hydrophilic polymer which, in some embodiments, bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used in some embodiments, for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates, in further embodiments, to methods of using and methods of making the peptides of the invention.

Hydrogels from biopolymers

Methods are disclosed for preparing linear or/and partial precross-linked poly-g-glutamic acid nanoparticle products, their reaction with compounds which contain vinyl groups, and the polymerization by chemical initiation or photopolymerization of these by light of predetermined wavelength. The final products of the present invention are useful as local drug delivery systems, dental surgery, and for inhibition of post-surgical adhesion. The hydrogels made from the biopolymers of the present invention may also be used in controlled release devices, superabsorbent materials and biomaterials like enzyme immobilization.

Peptides with an insulin-like action

Peptides with an insulin-like action, of formula I: STR1 in which G is a hydrogen atom, an amino add residue, or a monosubstituted or polysubstituted amino acid; D is an amino acid residue, a phosphoamino acid residue, a monosaccharide residue, or a covalent bond; E is --NH--(CH2)n --NR52, a glycerol residue, or --NH--(CH2)p --R6 --R7 ; R1 is (C1 -C4)-alkyl or =O; R2 is a sulfhydryl protecting group, (C1 -C3)-alkyl, or a hydrogen atom; R3 and R4, independently of one another, are a hydrogen atom or methyl; R5, each being identical or different, is a hydrogen atom, 1 to 6 monosaccharide residues, or 1 to 6 monosubstituted or polysubstituted monosaccharide residues; R6 is O PO4 H, PO2 H, NHCOO, S or OCOO; R7 is a hydrogen atom, 1 to 6 monosaccharide residues, or 1 to 6 monosubstituted or polysubstituted monosaccharide residues; w is an integer 1 or 2; their preparation and use for treatment of diabetes mellitus or insulin-independent diabetes.